Curetis Publishes Financial Results


Curetis AG / Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

– Company successfully completed IPO on Euronext Amsterdam and Euronext Brussels, raising EUR 44.3 million

 – Accelerated global commercialization lays strong foundation for future growth

Amsterdam, the Netherlands and Holzgerlingen, Germany, April 12, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced financial results for the twelve months ended December 31, 2015 and provided details on its outlook for 2016.

2015 Operational Highlights

  • Through its successful IPO on Euronext Amsterdam and Euronext Brussels, raised EUR 44.3 million, including the exercise of the overallotment option.
  • Significantly strengthened commercial capabilities by appointing Dr. Achim Plum as Chief Commercial Officer and expanding its direct sales channels beyond the DACH region (Germany, Austria, Switzerland) to also cover the UK, France and Benelux. Expanded commercial team to 12 members to facilitate broader direct sales efforts as well as marketing and business development support.
  • Entered major Asian markets through partnerships with Beijing Clear Biotech (BCB) for Mainland China, Hong Kong and Taiwan and with Singapore-based Acumen for ASEAN markets, which will initially include Singapore, Malaysia, Thailand and Indonesia.
  • As of the end of 2015, the Company has significantly grown the installed base of Unyvero Analyzers to 103, a 78% increase from an installed base of 58 at the end of 2014.
  • Partnered with an undisclosed major pharmaceutical company for a Phase III Amikacin drug trial. In this trial, Unyvero is being used for pathogen identification and patient inclusion at multiple clinical sites across Europe.

2015 Financial Highlights

  • Revenues: EUR 2.1 million (EUR 0.3 million in 2014).
  • Expenses: EUR 14.3 million total cost of sales, distribution costs, administrative expenses and research & development expenses (EUR 10.5 million in 2014). The increase was mainly due to the increase in valuation of Phantom Stock Options (PSOs).
  • Operating result: EUR 12.1 million (EUR 10.1 million in 2014).
  • Net profit / Net loss: EUR 13.8 million (net loss of EUR 12.4 million in 2014). The difference is mainly due to financial income totaling EUR 25.9 million net, which primarily resulted from a one-time IFRS accounting entry related to the changes in fair value measurement of the preferred and common shares of Curetis AG, which was triggered by the corporate reorganization of the Company.
  • Cash & cash equivalents: EUR 46.1 million as of Dec. 31, 2015 (EUR 3.0 million on December 31, 2014).
  • Net cash burn from operating activities: EUR 8.5 million (EUR 7.4 million in 2014)
  • Net cash burn from investing activities: EUR 1.1 million (EUR 1.6 million in 2014).

Anticipated Milestones

  • Based on current forecasts and expansion plans, Curetis anticipates that the Unyvero Installed Base will grow to 150 to 200 systems at the end of 2016, adding between 50 and 100 new Unyvero Analyzers globally to the installed base during the year.
  • Curetis will add multiple new Application Cartridges to the portfolio of the Unyvero Solution and accelerate its development pipeline in 2016 and 2017. During ECCMID 2016, the Company launched its Unyvero BCU (Blood Culture) Cartridge as a CE-IVD marked product in Europe. Furthermore, the Company expects to launch a second generation of its ITI (implant and tissue infection) Application Cartridge in mid-2016. Toward the end of 2016, the Company anticipates the completion of product development for an IAI panel (intra-abdominal infection) and in late 2017, development of a Sepsis Host Response Application Cartridge.
  • In 2016, Curetis expects its US clinical trial to progress toward completion. With more than 1,600 patient samples already enrolled and successfully tested by the end of March 2016, the Company believes that it will complete enrolment by mid-year and expects to be in a position to submit its application for US FDA clearance of Unyvero in the second half of 2016. The Company aims for FDA clearance of its Unyvero LRT55 product in the first half of 2017, provided that the FDA trial will be successfully completed in 2016.
  • In line with the expected US FDA clearance, the Company intends to build its own direct US marketing and sales organization, beginning with the recruitment of a core team in the second half of 2016. An executive search for the US General Manager / US CEO is currently ongoing.
  • The Company expects that its partner BCB will drive toward completion of its CFDA trial in China by early 2017. BCB has expressed its goal to obtain CFDA clearance in 2017 and to begin commercialization in mainland China thereafter. Commercial efforts in Hong Kong and Taiwan, which are not subject to first obtaining CFDA approval, have already begun with initial installations at major hospitals expected during 2016.

Commenting on Curetis’ 2015 results, Oliver Schacht, CEO of the Company stated: “The year 2015 was extremely successful for Curetis. Based on the three-pronged strategy of expanding Curetis’ commercial presence in Europe, building our own direct US commercial presence and accelerating our Unyvero product development pipeline, we were able to up-size our IPO in November by more than 50% compared to our original target. Throughout 2015 and into 2016 we have begun executing on our strategic plans and further developing our equity story in line with what we communicated during our IPO. Key additions to our commercial team have been made and we expect to continue growing our sales and marketing capabilities. With a very solid cash position of more than 46 million Euros going into 2016, we are well positioned to continue executing this year, and well into the future.”

“At a macro level, Unyvero is beginning to make an impact on how critically ill patients with infectious diseases in hospitals get diagnosed and treated with antibiotics,” Schacht added. “Unyvero contributes to personalizing medicine, and empowers clinicians to make rational antibiotic treatment decisions for patients in life-threatening situations.”

For the twelve months ended December 31, 2015, revenues were EUR 2.1 million, a substantial increase over revenues of EUR 0.3 million in 2014. The strong revenue growth was primarily attributable to a 78% increase in the installed base of Unyvero Analyzers, which totaled 103 at the end of 2015, compared to 58 as of the end of 2014.

Gross loss for the year totaled EUR 0.07 Million, compared with a gross loss of EUR 0.37 Million in 2014. The gross loss was primarily attributable to significant revenues from Unyvero system sales in 2015 at very low or no margins, as well as discounted pricing of Unyvero cartridges sold to distribution partners for clinical trials. Also, under IFRS accounting the cost of goods for the Unyvero cartridges still include significant elements of as-yet unutilized capacity to allow for future expansion in manufacturing output. Full-year 2015 gross margin was -3.5%, compared with -134% for 2014.

Operating loss in 2015 totaled EUR 12.1 million, compared with EUR 10.1 million in 2014. The increased operating loss was mainly related to acceleration of the Company’s commercial expansion and an increase in valuation of the PSOs resulting from the IPO.

Net income for the year was EUR 13.8 million compared with a net loss of EUR 12.4 million in 2014. Full-year 2015 net income included financial income of EUR 25.9 million net, mainly relating to the changes in fair value measurement of the preferred and common shares of Curetis AG, which was triggered by the corporate reorganization of the Company in preparation for its IPO in November 2015.

At the end of 2016, the Company expects a strong cash position of EUR 31 to 32 million cash on hand and a net cash burn of EUR 14 to 15 million throughout the year for all operating and investment activities combined.

Earnings Conference Call and Webcast
Curetis will host a public earnings conference call and webcast today, April 12, 2016, at 03:00pm CET / 09:00am EST to discuss the financial results of 2015, highlight the most important events and provide an outlook for 2016.

The conference call will be supplemented by a presentation which can be accessed during the call at

To access the call, please dial the following numbers using the passcode 93120684#
Germany: +49 69 222229043
UK: +44 20 30092452
US: +1 855 4027766
For further international dial-in numbers, please open the following link: Access Numbers_ UKFELBRI1_SU7.pdf

For following the presentation during the telephone call, please access the webcast at:
The access code is: curetis0416

The live webcast and a replay (with sound) will be available at

The full annual financial report 2015 will be available as of today, April 12, 2016, at



CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.


About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.

For further information, please visit

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment in the commercial register at district court Stuttgart on March 15, 2016 Curetis plc (AG) changed its legal form into Curetis Ltd. (GmbH).

Contact details
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10 or

International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
Tel. +1 646 536 7012



For the years ended December 31

in Euro 2015 2014
Revenue 2,086,726 274,552
Cost of sales 2,160,778 642,519
Gross loss -74,052 -367,967
Distribution costs 2,786,967 1,939,334
Administrative expenses 2,598,424 1,637,406
Research & development expenses 6,712,341 6,297,554
Other income 121,139 110,600
Operating loss -12,050,645 -10,131,661
Finance income 29,566 5,754
Finance costs 1,929,762 22,363
Finance income / costs fair value measurement -27,790,433 2,285,652
Finance costs – net 25,890,237 -2,302,261
Profit / loss before income tax 13,839,592 -12,433,922
Income tax expenses
Profit / loss for the year 13,839,592 -12,433,922
Other comprehensive income for the year, net tax
Total comprehensive income for the year 13,839,592 -12,433,922
Earnings / loss per share 2015 2014
Basic 1.18 -9.48
Diluted 1.18 -9.48


As at 31 December 2015


in Euro 31.12.2015 31.12.2014
Current assets   50,573,547 6,485,882
Cash and cash equivalents 46,060,397 2,993,883
Trade receivables 1,072,131 42,235
Inventories 2,786,887 3,153,137
Other current assets 654,132 296,627
Non-current assets 6,823,465 7,307,395
Intangible assets 645,120 286,355
Property, plant and equipment 5,605,496 6,591,674
Other non-current assets 223,846 390
Other non-current financial assets 349,003 428,976
Deferred tax assets
Total assets   57,397,012 13,793,277


As at 31 December 2015

Liability & Equity

  in Euro 31.12.2015 31.12.2014
Current liabilities 2,446,095 1,304,748
Trade and other payables 863,342 579,862
Liability PSOP 367,308
Provisions current 29,300 34,800
Other current liabilities 676,502 316,817
Other current financial liabilities 509,643 373,269
Non-current liabilities 155,926 131,024,233
Provisions non current 38,035 816,065
Provision PSOP 3,913,841
Other non-current financial liabilities 117,891 258,168
Financial liability for preferred and common shares 126,036,159
Deferred tax liability
Total liabilities   2,602,021 132,328,981
Equity   54,794,991 -118,535,704
Share capital 155,384 50,000
Capital reserve 152,793,347
Other reserves 6,592,372
Retained earnings -104,746,112 -118,585,704
Total Equity and liabilities 57,397,012 13,793,277


For the years ended December 31

in Euro
2015 2014
Profit before income tax 13,839,592 -12,433,922
Adjustment for:
– Net finance income / costs -25,890,237 2,302,261
– Depreciation, amortization and impairments 1,708,401 1,448,455
– Gain on disposal of fixed assets 15,586 38,161
– Changes in provisions -784,082 1,023,028
– Changes in valuation of PSOP-liability 3,045,839 0
– Net exchange differences -10,404 1,475
Changes in working capital relating to:
– Inventories 366,250 -367,143
– Trade receivables and other receivables -1,530,884 382,767
– Trade payables and other payables 773,011 179,807
Income taxes received (+) / paid (-) 0 0
Interests paid (-) -30,423 -22,363
Net cash flow provided by operating activities -8,497,351 -7,447,474
Payments for intangible assets -487,439 -66,878
Payments for property, plant and equipment -608,583 -1,512,013
Proceeds from sale of property, plant and equipment 0 4,000
Interests received 29,566 5,754
Net cash flow used in investing activities -1,066,456 -1,569,137
Payments for finance lease liabilities -133,749 -127,523
Cash received from capital increase 13,578,054 6,757,529
Proceeds from issue of ordinary shares 44,310,330 0
Payments for financing costs for IPO of old shares -1,899,339 0
Transaction costs for issue of ordinary shares -3,235,379 0
Net cash flow provided by financing activities 52,619,917 6,630,006
Net increase (decrease) in cash and cash equivalents 43,056,110 -2,386,605
Net cash and cash equivalents at the beginning of the year 2,993,883 5,381,963
Net increase (decrease) in cash and cash equivalents 43,056,110 -2,386,605
Effects of exchange rate changes on cash and cash equivalents 10,404 -1,475
Net Cash and cash equivalents at the end of the year 46,060,397 2,993,883

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.